AstraZeneca PLC (NASDAQ:AZN) Stock Position Decreased by Capital Advisors Inc. OK

Capital Advisors Inc. OK trimmed its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 6.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,436 shares of the company’s stock after selling 287 shares during the quarter. Capital Advisors Inc. OK’s holdings in AstraZeneca were worth $346,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in AZN. Americana Partners LLC boosted its holdings in AstraZeneca by 1.4% in the third quarter. Americana Partners LLC now owns 28,413 shares of the company’s stock worth $2,214,000 after purchasing an additional 395 shares in the last quarter. Gladstone Institutional Advisory LLC raised its holdings in AstraZeneca by 7.4% during the third quarter. Gladstone Institutional Advisory LLC now owns 2,893 shares of the company’s stock valued at $225,000 after buying an additional 199 shares in the last quarter. Focus Financial Network Inc. lifted its position in shares of AstraZeneca by 9.1% in the third quarter. Focus Financial Network Inc. now owns 5,295 shares of the company’s stock worth $412,000 after buying an additional 441 shares during the last quarter. Oak Ridge Investments LLC boosted its stake in shares of AstraZeneca by 7.2% during the 3rd quarter. Oak Ridge Investments LLC now owns 136,632 shares of the company’s stock worth $10,645,000 after acquiring an additional 9,141 shares in the last quarter. Finally, US Bancorp DE increased its holdings in shares of AstraZeneca by 6.9% during the 3rd quarter. US Bancorp DE now owns 232,419 shares of the company’s stock valued at $18,108,000 after acquiring an additional 14,965 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. TD Cowen upped their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at $71.42 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The company has a market cap of $221.44 billion, a PE ratio of 34.50, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. The firm has a fifty day moving average price of $79.17 and a two-hundred day moving average price of $78.67. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.